Literature DB >> 24086039

Receptor tyrosine kinases in the nucleus.

Graham Carpenter1, Hong-Jun Liao.   

Abstract

To date, 18 distinct receptor tyrosine kinases (RTKs) are reported to be trafficked from the cell surface to the nucleus in response to ligand binding or heterologous agonist exposure. In most cases, an intracellular domain (ICD) fragment of the receptor is generated at the cell surface and translocated to the nucleus, whereas for a few others the intact receptor is translocated to the nucleus. ICD fragments are generated by several mechanisms, including proteolysis, internal translation initiation, and messenger RNA (mRNA) splicing. The most prevalent mechanism is intramembrane cleavage by γ-secretase. In some cases, more than one mechanism has been reported for the nuclear localization of a specific RTK. The generation and use of RTK ICD fragments to directly communicate with the nucleus and influence gene expression parallels the production of ICD fragments by a number of non-RTK cell-surface molecules that also influence cell proliferation. This review will be focused on the individual RTKs and to a lesser extent on other growth-related cell-surface transmembrane proteins.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24086039      PMCID: PMC3783051          DOI: 10.1101/cshperspect.a008979

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN: 1943-0264            Impact factor:   10.005


  171 in total

1.  Regulated intramembrane cleavage of the EGF receptor.

Authors:  Hong-Jun Liao; Graham Carpenter
Journal:  Traffic       Date:  2012-05-15       Impact factor: 6.215

Review 2.  The regulatory crosstalk between kinases and proteases in cancer.

Authors:  Carlos López-Otín; Tony Hunter
Journal:  Nat Rev Cancer       Date:  2010-03-19       Impact factor: 60.716

Review 3.  p95HER2 and breast cancer.

Authors:  Joaquín Arribas; José Baselga; Kim Pedersen; Josep Lluís Parra-Palau
Journal:  Cancer Res       Date:  2011-02-22       Impact factor: 12.701

4.  EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment.

Authors:  Gianmaria Liccardi; John A Hartley; Daniel Hochhauser
Journal:  Cancer Res       Date:  2011-01-25       Impact factor: 12.701

5.  VEGFR2 translocates to the nucleus to regulate its own transcription.

Authors:  Inês Domingues; José Rino; Jeroen A A Demmers; Primal de Lanerolle; Susana Constantino Rosa Santos
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

6.  EpCAM regulates cell cycle progression via control of cyclin D1 expression.

Authors:  A Chaves-Pérez; B Mack; D Maetzel; H Kremling; C Eggert; U Harréus; O Gires
Journal:  Oncogene       Date:  2012-03-05       Impact factor: 9.867

7.  Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1.

Authors:  Jun Cai; Wen G Jiang; Maria B Grant; Mike Boulton
Journal:  J Biol Chem       Date:  2005-12-08       Impact factor: 5.157

8.  A nuclear variant of ErbB3 receptor tyrosine kinase regulates ezrin distribution and Schwann cell myelination.

Authors:  Tadepalli Adilakshmi; Jennifer Ness-Myers; Carlos Madrid-Aliste; Andras Fiser; Nikos Tapinos
Journal:  J Neurosci       Date:  2011-03-30       Impact factor: 6.167

9.  Epithelial cell adhesion molecule (EpCAM) complex proteins promote transcription factor-mediated pluripotency reprogramming.

Authors:  Hsiang-Po Huang; Pin-Hsun Chen; Chun-Ying Yu; Ching-Yu Chuang; Lee Stone; Wen-Chu Hsiao; Chung-Leung Li; Shih-Chih Tsai; Kai-Yun Chen; Hsin-Fu Chen; Hong-Nerng Ho; Hung-Chih Kuo
Journal:  J Biol Chem       Date:  2011-07-28       Impact factor: 5.157

10.  Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease.

Authors:  Gen He; Wenjie Luo; Peng Li; Christine Remmers; William J Netzer; Joseph Hendrick; Karima Bettayeb; Marc Flajolet; Fred Gorelick; Lawrence P Wennogle; Paul Greengard
Journal:  Nature       Date:  2010-09-02       Impact factor: 49.962

View more
  46 in total

Review 1.  Nuclear Fibroblast Growth Factor Receptor Signaling in Skeletal Development and Disease.

Authors:  Creighton T Tuzon; Diana Rigueur; Amy E Merrill
Journal:  Curr Osteoporos Rep       Date:  2019-06       Impact factor: 5.096

Review 2.  MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment.

Authors:  Donald W Kufe
Journal:  Carcinogenesis       Date:  2020-09-24       Impact factor: 4.944

3.  An Overdose of the Arabidopsis Coreceptor BRASSINOSTEROID INSENSITIVE1-ASSOCIATED RECEPTOR KINASE1 or Its Ectodomain Causes Autoimmunity in a SUPPRESSOR OF BIR1-1-Dependent Manner.

Authors:  Ana Domínguez-Ferreras; Marta Kiss-Papp; Anna Kristina Jehle; Georg Felix; Delphine Chinchilla
Journal:  Plant Physiol       Date:  2015-05-05       Impact factor: 8.340

Review 4.  Non-canonical signaling mode of the epidermal growth factor receptor family.

Authors:  Heng-Huan Lee; Ying-Nai Wang; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

5.  The Drosophila Epidermal Growth Factor Receptor does not act in the nucleus.

Authors:  Maximilien Courgeon; Dan Qing He; Hui Hua Liu; Kevin Legent; Jessica E Treisman
Journal:  J Cell Sci       Date:  2018-09-20       Impact factor: 5.285

Review 6.  Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?

Authors:  Rosalía I Cordo Russo; María F Chervo; Santiago Madera; Eduardo H Charreau; Patricia V Elizalde
Journal:  Horm Cancer       Date:  2019-01-17       Impact factor: 3.869

7.  Nuclear trafficking of EGFR by Vps34 represses Arf expression to promote lung tumor cell survival.

Authors:  D Dayde; M Guerard; P Perron; A-S Hatat; C Barrial; B Eymin; S Gazzeri
Journal:  Oncogene       Date:  2015-12-21       Impact factor: 9.867

Review 8.  Effective implementation of novel MET pharmacodynamic assays in translational studies.

Authors:  Apurva K Srivastava; Tony Navas; William G Herrick; Melinda G Hollingshead; Donald P Bottaro; James H Doroshow; Ralph E Parchment
Journal:  Ann Transl Med       Date:  2017-01

9.  Recepteur d'Origine nantais (RON) tyrosine kinase splicing variants lacking exons 18 and 19 occur ubiquitously in lung cancer.

Authors:  Soundararajan Krishnaswamy; Abdul Khader Mohammed; Osama E Amer; Gyanendra Tripathi; Majed S Alokail; Nasser M Al-Daghri
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 10.  Metabotropic glutamate receptor trafficking.

Authors:  Young Ho Suh; Kai Chang; Katherine W Roche
Journal:  Mol Cell Neurosci       Date:  2018-03-29       Impact factor: 4.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.